Продуктово разработване

Терапии в процес на разработка

Нашите екипи за изследователска и развойна дейност се стремят да проучват основните механизми на мозъчните заболявания. Заедно работим за постигане на общата ни цел - осигуряване на нови терапии, които предефинират стандарта за лечение на пациентите и са насочени към мозъчните заболявания с най-голяма протребност.
хормонална / невропептидна сигнализация
Проект за продуктово разработване Област на продуктово разработване Фаза 1 Фаза 2 Фаза 3 Подаване за регистрация
Eptinezumab (anti-CGRP mAb)* Migraine prevention Filing

Механизъм на действие

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

*Three phase III clinical trials (SUNLIGHT, SUNRISE, and SUNSET) are related to the Asia registration activities.

Eptinezumab (anti-CGRP mAb) Cluster headache 3

Механизъм на действие

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Lu AG09222 (anti-PACAP mAb) Migraine prevention 2

Механизъм на действие

Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology.

Lu AG13909 (anti-ACTH mAb) Neurohormonal dysfunctions 1

Механизъм на действие

Lu AG13909 is a humanized anti-adrenocorticotropic hormone (anti-ACTH) monoclonal antibody that blocks the binding of ACTH to the melanocortin 2 receptor in the adrenal glands, thereby decreasing the neurohormonal signaling of ACTH.

верижна / невронална биология
Проект за продуктово разработване Област на продуктово разработване Фаза 1 Фаза 2 Фаза 3 Подаване за регистрация
Aripiprazole 2-month injectable* Schizophrenia + Bipolar I disorder Filing

Механизъм на действие

A 2-month injectable aripiprazole formulation in an extended dosing interval has the potential to improve adherence to treatment and provide continuous exposure to medication, relevant to the clinical outcomes in adult patients with schizophrenia or BP-I. 

*Clinical program finalized; Lundbeck and Otsuka Pharmaceutical have submitted the aripiprazole 2-month injectable formulation to the European Medicines Agency (EMA) for marketing authorization application (MAA) review and as well as to the US Food & Drug Administration (FDA). 

Is approved in the U.S.

Brexpiprazole* Agitation in Alzheimer's disease (AADAD) Filing

Механизъм на действие

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

AADAD: Agitation Associated with Dementia due to Alzheimer’s Disease.

Is approved in the U.S.

Brexpiprazole* PTSD 3

Механизъм на действие

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD (post-traumatic stress disorder) symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AF28996 (D1-D2 agonist) Parkinson's disease 1

Механизъм на действие

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

MAGLi program Psychiatry + Neurology 1

Механизъм на действие

The MAGL inhibitor program consists of several small molecules and highly selective inhibitors of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and decrease neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications within Neurology and Psychiatry.

Протеинова агрегация, сгъване и клирънс
Проект за продуктово разработване Област на продуктово разработване Фаза 1 Фаза 2 Фаза 3
Lu AF82422 (anti-alpha-synuclein mAb) Synucleinopathies (MSA) 2

Механизъм на действие

Lu AF82422 is a monoclonal antibody (mAb) targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Multiple System Atrophy (MSA), Parkinson’s disease and other neurodegenerative disorders.

невровъзпаление / невроимунология
Проект за продуктово разработване Област на продуктово разработване Фаза 1 Фаза 2 Фаза 3
Lu AG22515 (CD40L blocker)* Neurology 1

Механизъм на действие

Lu AG22515 is a CD40L blocker, which interferes with the activation of the adaptive immune response by inhibiting the CD40L/CD40 co-stimulatory interaction on immune cells; an interaction, which plays a role in the pathophysiology of several immune-mediated diseases.

* CD40L/serum-albumin bispecific antibody-fragment ((scFv)2-Fab)) based on AprilBio’s SAFA™ technology platform.

Още от Лундбек

Изследователска и развойна дейност

Изследването и разработването на нови и подобрени лекарства е в основата на нашата дейност.

За нас

Лундбек е глобална фармацевтична компания, специализирана в мозъчни заболявания.

Разбиране на мозъчните заболявания

Пътят към здравето на мозъка започва с разбиране на заболяванията в мозъка.